Aldevron, a global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, has entered a strategic partnership with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs).
Aldevron Announces Strategic Partnership with Acuitas Therapeutics
REDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with...
Aldevron, a global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, is expanding its mRNA production capabilities to include lipid nanoparticle?(LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from master cell bank?through to drug product. The expansion is expected to be fully online in the second half of 2023.
Aldevron, a subsidiary of Danaher, unveiled plans to expand its mRNA manufacturing operations to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities.
En route to entering the clinic with its first AAV-based gene therapy for a rare neuromuscular disease, AavantiBio has let go of 30 employees, Endpoints News has learned.
Fargo-based DNA and mRNA producer Aldevron has signed an agreement with life sciences company Inscripta to manufacture and commercialize the Eureca-V Nuclease, a wild-type MAD7 CRISPR Type-V nuclease.
Aldevron, a research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, and Ginkgo Bioworks, Inc., announced a manufacturing breakthrough leveraging their strategic partnership.
After partnering with biomanufacturing expert Aldevron earlier this year, Ginkgo Bioworks has notched a win in the red-hot mRNA manufacturing field.
After partnering with biomanufacturing expert Aldevron earlier this year, Ginkgo Bioworks has notched a win in the red-hot mRNA manufacturing field.